Actively Recruiting
Validation of RCC Predicting Model With Emulated-target Trial
Led by Peking University Third Hospital · Updated on 2026-04-14
4700
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
CONDITIONS
Official Title
Validation of RCC Predicting Model With Emulated-target Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 65 18 years of age
- Diagnosis of primary renal cell carcinoma before and during the surgery
- Received radical nephrectomy or nephron-sparing surgery
You will not qualify if you...
- Subjects with severely missing clinical information
- History of other malignant tumors
- Recurrence observed before first postoperative follow-up
- Discontinued adjuvant treatment within first two courses due to severe adverse reactions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
J
Jiyuan Chen, master
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here